Current Rating and Its Significance
MarketsMOJO assigns Alembic Pharmaceuticals Ltd. a 'Hold' rating, indicating a neutral stance on the stock. This suggests that investors should neither aggressively buy nor sell the shares at present but rather monitor the company’s developments closely. The 'Hold' rating reflects a balance of strengths and weaknesses across key evaluation parameters, signalling that the stock may offer moderate returns with some risks to consider.
Quality Assessment
As of 25 August 2026, Alembic Pharmaceuticals exhibits an average quality grade. The company maintains a strong ability to service its debt, with a low Debt to EBITDA ratio of 1.28 times, which is a positive indicator of financial stability. However, the long-term growth outlook remains subdued, as operating profit has declined at an annualised rate of -6.71% over the past five years. This mixed quality profile suggests that while the company is financially sound, its growth momentum has been lacking.
Valuation Perspective
The valuation grade for Alembic Pharmaceuticals is currently attractive. The stock trades at a discount relative to its peers, with an enterprise value to capital employed ratio of 2.5, which is considered reasonable for the pharmaceuticals sector. Additionally, the company’s return on capital employed (ROCE) stands at 11.6%, supporting the view that the stock is fairly valued. The price-to-earnings-to-growth (PEG) ratio of 0.8 further indicates that the stock may be undervalued relative to its earnings growth potential, making it appealing for value-conscious investors.
Financial Trend Analysis
Financially, Alembic Pharmaceuticals shows a flat trend. The latest quarterly results for June 2026 were largely steady, with interest expenses reaching Rs 27.61 crores, the highest recorded for the company. Despite this, profits have risen by 27.1% over the past year, a positive sign amid a challenging market environment. However, the stock’s price performance has not mirrored this improvement, with a one-year return of -17.62%, significantly underperforming the BSE500 index, which gained 1.39% over the same period. This divergence between profit growth and share price performance highlights some market scepticism or external pressures affecting the stock.
Technical Outlook
From a technical standpoint, the stock is mildly bullish. Recent price movements show modest gains over the past three and six months, with returns of +5.74% and +9.24% respectively. However, short-term performance has been mixed, with a one-day decline of -0.98% and a one-week drop of -2.24%. The technical grade suggests cautious optimism, indicating that while the stock may have some upward momentum, investors should be mindful of volatility and market conditions.
Stock Returns and Market Comparison
As of 25 August 2026, Alembic Pharmaceuticals’ stock has delivered a year-to-date return of -4.90%, reflecting a challenging environment for the company’s shares. Over the last twelve months, the stock has underperformed the broader market, with a negative return of -17.62% compared to the BSE500’s positive 1.39%. This underperformance underscores the importance of the 'Hold' rating, signalling that investors should weigh the company’s fundamental strengths against its recent price weakness.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
Implications for Investors
The 'Hold' rating on Alembic Pharmaceuticals Ltd. advises investors to maintain their current positions without initiating new purchases or sales. The company’s attractive valuation and stable financial footing provide a cushion against downside risks, but the lack of strong growth and recent underperformance suggest limited upside potential in the near term. Investors should monitor upcoming quarterly results and sector developments closely to reassess the stock’s prospects.
Sector and Market Context
Operating within the Pharmaceuticals & Biotechnology sector, Alembic Pharmaceuticals faces competitive pressures and regulatory challenges that can impact growth trajectories. The sector has seen varied performance, with some peers delivering robust returns while others struggle with pricing pressures and innovation cycles. Alembic’s current position reflects these dynamics, balancing solid fundamentals with cautious market sentiment.
Summary of Key Metrics as of 25 August 2026
To summarise, the stock’s key metrics include a Mojo Score of 58.0, reflecting a moderate overall outlook. The company’s debt servicing capability remains strong, with a Debt to EBITDA ratio of 1.28 times. Operating profit has declined over the past five years at an annualised rate of -6.71%, while profits have grown 27.1% in the last year. The stock trades at an enterprise value to capital employed ratio of 2.5 and a ROCE of 11.6%, supporting its attractive valuation grade. Despite these positives, the stock’s one-year return of -17.62% highlights the need for cautious investment consideration.
Conclusion
Alembic Pharmaceuticals Ltd.’s 'Hold' rating by MarketsMOJO reflects a balanced view of the company’s current fundamentals, valuation, financial trends, and technical outlook. While the stock offers value and financial stability, growth challenges and recent price underperformance temper enthusiasm. Investors are advised to maintain a watchful stance, considering the stock as a potential candidate for accumulation only if future quarters demonstrate renewed growth momentum and improved market sentiment.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
